 |
MR Vol.11 No.2 indexに戻る
 |
MODERN RHEUMATOLOGY
Vol.11 No.2 |
 |
|
|
 |
|
|
Long-term use of mizoribine in rheumatoid
arthritis patients on hemodialysis |
|
|
| K. Saisho1, O. Kurosawa1, T. Fukanoki1,
A. Hanafusa2, N. Tajima3 |
(1)Department of Orthopedics, National Miyakonojo
Hospital, 5033-1 Iwayoshi, Miyakonojo, Miyazaki 885-0014, Japan
Tel. +81-986-23-4111; Fax +81-986-24-3964
(2)
Hanafusa Urology Hospital,
Miyazaki, Japan
(3)Department of Orthopedics, Miyazaki Medical University, Miyazaki, Japan |
| |
| Abstract |
| Abstract Small doses of mizoribine (MZR) were
administered to five rheumatoid arthritis (RA) patients on hemodialysis
(HD). A maintenance dose of 25 mg or less was administered either
once per day or once following HD. The Lansbury activity index improved
in all patients. The blood concentrations of MZR before and after
HD were 0.33-1.79 7g/ml and 0-0.93 7g/ml, respectively. Hence, the
rate of elimination by HD ranged from 50.3% to 83.4%. As far as side
effects were concerned, alopecia was seen in two patients, and one
patient developed shingles. However, the severity of these symptoms
was mild and, after discontinuing or reducing the dose of MZR for
a certain period of time, we were able to continue its administration.
These findings suggest that the long-term administration of MZR is
a useful treatment for RA patients on HD. |
| |
| Key words |
| Key words Disease-modifying antirheumatic
drug ・ Hemodialysis ・ Mizoribine ・ Rheumatoid arthritis |
|
|
 |
|
|
